Literature DB >> 27770837

Effect of Riboflavin/UVA Collagen Cross-linking on Central Cornea, Limbus and Intraocular Pressure. Experimental Study in Rabbit Eyes.

Vassilios Kozobolis1, Maria Gkika1, Haris Sideroudi2, Efthymia Tsaragli1, Stylliani Lydataki3,4, Irini Naoumidi4, Alexandra Giatromanolaki5, Dimitrios Mikropoulos6, Miguel Teus7, Georgios Labiris1.   

Abstract

The Purpose of present study was to investigate the effect of riboflavin/ultraviolet-A-induced collagen cross-linking (CXL) on central cornea, limbus and intraocular pressure (IOP). This was an animal experimental study. The right corneas of 10 rabbits were ultraviolet-A irradiated (3 mW/cm2 for 30 minutes) after de-epithelialization and instillation of 0.1% riboflavin / 20% Dextran drops. Left corneas served as controls. Samples were examined histologically one month postoperatively. Before and after treatment, IOP measurements were recorded bilaterally. At central cornea of eyes underwent CXL keratocyte repopulation, normal arrangement of collagen fibres and a statistically significant change in fibres diameter were detected, compared to controls. At limbus area, there were not any significant histological differences after CXL. There was no statistically significant difference between pre- and postoperative IOP in all eyes.

Entities:  

Keywords:  Cornea; Corneal Crosslinking; Intraocular pressure; Limbus

Mesh:

Substances:

Year:  2016        PMID: 27770837     DOI: 10.14712/18059694.2016.96

Source DB:  PubMed          Journal:  Acta Medica (Hradec Kralove)        ISSN: 1211-4286


  2 in total

1.  Nonlinear Optical Corneal Crosslinking, Mechanical Stiffening, and Corneal Flattening Using Amplified Femtosecond Pulses.

Authors:  Samantha Bradford; Eric Mikula; Sun Woong Kim; Yilu Xie; Tibor Juhasz; Donald J Brown; James V Jester
Journal:  Transl Vis Sci Technol       Date:  2019-12-16       Impact factor: 3.283

Review 2.  Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases.

Authors:  Duoduo Wu; Dawn Ka-Ann Lim; Blanche Xiao Hong Lim; Nathan Wong; Farhad Hafezi; Ray Manotosh; Chris Hong Long Lim
Journal:  Front Pharmacol       Date:  2021-07-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.